GC Therapeutics
Chih-Chao Yang has an extensive background in biomedical sciences and extensive experience in various research roles. From their time as a Research Assistant at Academia Sinica to their current position as a Senior Scientist II at GC Therapeutics, Chih-Chao has focused on utilizing CRISPR/Cas9 technology for gene editing and cell line development. Chih-Chao has a strong track record of project management, team leadership, and delivering results in a timely manner. Chih-Chao's educational background includes a Ph.D. in Biomedical Sciences from The University of Texas Health Science Center at Houston.
GC Therapeutics
1 followers
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.